Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Adult-onset leukoencephalopathy with axonal spheroids Indication Strategy Report 2026: CSF1R, Trials and Deals
23 July 2026
2026 Adult-onset leukoencephalopathy with axonal spheroids strategy: epidemiology, CSF1R biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Post-polio syndrome Indication Strategy Report 2026: IGF-1, Trials and Deals
23 July 2026
2026 Post-polio syndrome strategy: epidemiology, IGF-1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Progressive muscular atrophy Indication Strategy Report 2026: SOD1, Trials and Deals
23 July 2026
2026 Progressive muscular atrophy strategy: epidemiology, SOD1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary lateral sclerosis Indication Strategy Report 2026: SOD1, Trials and Deals
23 July 2026
2026 Primary lateral sclerosis strategy: epidemiology, SOD1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Unverricht-Lundborg disease Indication Strategy Report 2026: CSTB, Trials and Deals
23 July 2026
2026 Unverricht-Lundborg disease strategy: epidemiology, CSTB biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinal and bulbar muscular atrophy Indication Strategy Report 2026: Androgen receptor, Trials and Deals
23 July 2026
2026 Spinal and bulbar muscular atrophy strategy: epidemiology, Androgen receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lafora disease Indication Strategy Report 2026: GYS1, Trials and Deals
23 July 2026
2026 Lafora disease strategy: epidemiology, GYS1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Progressive myoclonic epilepsy Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Progressive myoclonic epilepsy strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Juvenile myoclonic epilepsy Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Juvenile myoclonic epilepsy strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Epilepsy with myoclonic-atonic seizures Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Epilepsy with myoclonic-atonic seizures strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Neonatal seizures Indication Strategy Report 2026: KCNQ2, Trials and Deals
23 July 2026
2026 Neonatal seizures strategy: epidemiology, KCNQ2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Antisynthetase syndrome Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Antisynthetase syndrome strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.